Aderis Pharmaceuticals - News

Nov 4, 2002	Aderis Pharmaceuticals to Present At CIBC World Markets 13th Annual Health Care Conference
	For the audiocast of the Aderis presentation go to the Aderis Pharmaceuticals Events page and click on the CIBC logo.

Oct 7, 2002	Aderis Pharmaceuticals To Present At UBS Warburg Global Life Sciences Conference
	Company Comments On The Release Of Preliminary Findings Of Phase II TrialOf Rotigotine CDS In Restless Legs Syndrome Completed by SCHWARZ PHARMA AG

Aug 6, 2002	Aderis Pharmaceuticals Appoints Todd Brady, M.D., Ph.D. As Senior Director Of Business Development
	Proven ability to manage multi-million dollar licensing deals and partnerships in the biotechnology industry will be invaluable as we continue to expand our portfolio of products to treat CNS and cardiovascular diseases

Jul 29, 2002	Aderis Pharmaceuticals Appoints Joseph R. Bianchine, M.D., Ph.D., F.A.C.P., F.A.C.C.P., To Scientific Advisory Board
	Extensive experience in Parkinson's research and clinical pharmacology.

Feb 4, 2002	Aderis Pharmaceuticals Appoints Nobel Laureate Paul Greengard, Ph.D., to Scientific Advisory Board


Jan 7, 2002	Discovery Therapeutics Changes Name to Aderis Pharmaceuticals
	Name change reflects achievement of corporate and clinical milestones including initiation of Phase III clinical trials for first Parkinson�s patch.



	"At Aderis, we are excited about the progress of our product candidates and their potential ability to improve quality of life for millions of people. We are committed to helping patients and investors understand our progress as we achieve corporate and clinical milestones." -Kenneth L. Rice, Jr., Chief Commercial Officer, Aderis Pharmaceuticals


© 2001 - 2004 ADERIS Pharmaceuticals, Inc. Trademarks and Terms of Use		Created by PixelMEDIA, Inc. © 2003